Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01478048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Elotuzumab
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Dexamethasone
DRUG: Dexamethasone
DRUG: Dexamethasone

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]